Understand how psoriatic arthritis increases heart disease risk through inflammation. Learn management tips for heart health, from lifestyle changes to medication discussions.

In July 2025, Janssen Research & Development LLC conducted a study is to evaluate the efficacy of icotrokinra compared to ...

The exact cause of psoriatic arthritis isn't known, but the immune system plays a major role in its development. In general, ...

While IL-17 blocking agents are linked to an increased risk for candidiasis, bimekizumab, which blocks two proteins ...

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Psoriatic arthritis can also cause pain at the points where tendons and ligaments attach to your bones—especially at the back of your heel (Achilles tendinitis) or in the sole of your foot ...

IL-17 inhibitors are approved for axial spondyloarthritis and psoriatic arthritis, but their effectiveness in heavily ...

Until recently, little was known about psoriatic arthritis (PsA), a disease first described and classified by the medical community in the 1970s. A 2008 Belgian study offered hope to people with ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.